指南与共识皮肤肿瘤

EORTC/USCLC/ISCL皮肤淋巴增殖性疾病管理共识

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
指南 / 共识 · Br J Dermatol · 2025-01-01

针对原发性皮肤CD4+小/中T细胞淋巴增殖性疾病、原发性皮肤肢端CD8+T细胞淋巴增殖性疾病和原发性皮肤边缘区淋巴瘤/淋巴增殖性疾病,EORTC、USCLC和ISCL基于两次调查、文献检索和共识会议制定分期、治疗和随访推荐,提出典型病例无需额外分期检查、低剂量放疗和病灶内糖皮质激素可作为初始治疗、部分亚型随访2年。

要点

  • 典型PCSM-TCLPD和肢端CD8+TCLPD无需除皮肤和外围淋巴结临床检查外的分期检查。
  • PCSM-TCLPD和肢端CD8+TCLPD可用低剂量放疗4-8 Gy而非≥20 Gy,PCMZL/LPD可用4 Gy。
  • 三种LPD均推荐病灶内糖皮质激素作为初始治疗,PCSM-TCLPD和肢端CD8+TCLPD随访2年可接受。

核心结论

  • 共识推荐反映主要皮肤淋巴瘤中心对皮肤LPD的管理和治疗共识,可能促进统一的分期、治疗和随访策略。

研究设计与样本

  • 通过EORTC-CLTG、USCLC和ISCL协作的30个皮肤淋巴瘤专家中心分发两次调查,结合广泛文献检索、两轮反馈和最终共识会议制定推荐。

主要发现

  • 先前调查显示对新术语的临床管理存在显著异质性,强调需要制定统一推荐。
  • 与当前实践和文献相比的重要变化包括典型PCSM-TCLPD和肢端CD8+TCLPD无需额外分期检查。
  • 低剂量放疗4-8 Gy可用于PCSM-TCLPD和肢端CD8+TCLPD,4 Gy可用于PCMZL/LPD,局部失败时可升级至20-24 Gy。
  • 病灶内糖皮质激素推荐作为所有三种LPD的初始治疗。
  • PCSM-TCLPD和肢端CD8+TCLPD可接受有限随访期2年。

关键数值与推荐

  • 典型PCSM-TCLPD和肢端CD8+TCLPD:除彻底皮肤和外围淋巴结临床检查外,不要求其他分期检查。
  • PCSM-TCLPD和肢端CD8+TCLPD:低剂量放疗4-8 Gy可用而非剂量≥20 Gy;PCMZL/LPD可用4 Gy;局部失败时可升级至20-24 Gy。
  • 所有三种LPD:病灶内糖皮质激素推荐作为初始治疗。
  • PCSM-TCLPD和肢端CD8+TCLPD:有限随访期2年可接受。

临床怎么用

  • 典型PCSM-TCLPD和肢端CD8+TCLPD患者可仅进行彻底皮肤和外围淋巴结临床检查,无需额外分期检查。
  • PCSM-TCLPD和肢端CD8+TCLPD可选用低剂量放疗4-8 Gy,PCMZL/LPD可选用4 Gy,局部失败时升级至20-24 Gy。
  • 三种LPD均可采用病灶内糖皮质激素作为初始治疗。
  • PCSM-TCLPD和肢端CD8+TCLPD随访2年可接受,每6个月检查一次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lymphoma centres on the effects of this new terminology on clinical management. The results revealed considerable heterogeneity and emphasized the need to develop uniform recommendations for management and treatment of these disorders. Our objective was to develop consensus recommendations for staging, treatment and follow-up in PCSM-TCLPD, acral CD8+ TCLPD and PCMZL/LPD. Two surveys with questions regarding staging, treatment and follow-up of cutaneous LPDs were distributed among 30 cutaneous lymphoma expert centres collaborating within the EORTC-CLTG, USCLC and ISCL. Consensus recommendations were formulated based on these surveys, an extensive literature search, two rounds of feedback and a final consensus meeting. Important changes compared with current practice and literature are as follows. (i) Staging examinations, other than thorough clinical examination of skin and peripheral lymph nodes, are not required in typical cases of PCSM-TCLPD and acral CD8+ TCLPD. (ii) Low-dose radiotherapy (4-8 Gy) can be used rather than dose ≥ 20 Gy for PCSM-TCLPD and acral CD8+ TCLPD, and 4 Gy can be used for PCMZL/LPD. The dose can be escalated to 20-24 Gy in the case of local failure. (iii) Intralesional corticosteroids are also recommended as initial treatment in all three LPDs. (iv) A limited follow-up period (2 years) is acceptable in PCSM-TCLPD and acral CD8+ TCLPD LPD. These EORTC/USCLC/ISCL consensus recommendations reflect the state-of-the-art management and treatment as agreed upon by major cutaneous lymphoma centres. They may contribute to uniform staging, treatment and follow-up policy in patients with cutaneous LPDs. Cutaneous malignant lymphoma is a type of skin cancer. Three subtypes of this cancer have a benign clinical behaviour and respond well to treatment. Thus, they were recently reclassified as ‘cutaneous lymphoproliferative disorder’ (LPD). These new names are important as they reflect that these cancers are not malignant. The changes also prompted experts to update the guidance for their treatment. This study presents the new guidelines for LPDs. The study group included 30 centres from Europe and North and South America. They also collaborated with international lymphoma societies. The panel carried out surveys, a literature review and consensus meetings. The guidelines recommend several important changes. Thorough clinical examination is usually the only procedure required. Yet when needed, many treatment options are available. These include surgery, radiotherapy and corticosteroids. Watchful waiting is also suggested, with only symptomatic lesions treated. Follow-up is only required for 2 years, with checkups every 6 months. These recommendations will improve management and treatment in patients with cutaneous LPDs.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Willemze R, Assaf C, Bagot M, et al. European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. Br J Dermatol. 2025. PMID: 40795052. doi:10.1093/bjd/ljaf312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。